Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

NCT05383079 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer
MCRPC
Prostate Cancer

Interventions

DRUG: Lutetium-177 PSMA-I&T
DRUG: Radium-223

Sponsor

Peter MacCallum Cancer Centre, Australia